The evolving landscape of SARS-CoV-2 vaccination in Mexico: real-world evidence in Mexican pensioners.
作者信息
Antonio-Villa Neftali Eduardo, Bello-Chavolla Omar Yaxmehen, Fermín-Martínez Carlos A, Fernández-Chirino Luisa, Ramírez-García Daniel
机构信息
Departamento de Endocrinología, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.
Research Division, Instituto Nacional de Geriatría, Mexico City, Mexico.
出版信息
Lancet Reg Health Am. 2023 Oct 31;27:100624. doi: 10.1016/j.lana.2023.100624. eCollection 2023 Nov.
Abstract
摘要
相似文献
1
The evolving landscape of SARS-CoV-2 vaccination in Mexico: real-world evidence in Mexican pensioners.墨西哥2019冠状病毒病疫苗接种的发展态势：墨西哥养老金领取者的真实世界证据
Lancet Reg Health Am. 2023 Oct 31;27:100624. doi: 10.1016/j.lana.2023.100624. eCollection 2023 Nov.
2
Decrease in COVID-19 adverse outcomes in adults during the Delta and Omicron SARS-CoV-2 waves, after vaccination in Mexico.墨西哥接种疫苗后，德尔塔和奥密克戎 SARS-CoV-2 波期间成年人 COVID-19 不良结局减少。
Front Public Health. 2022 Sep 13;10:1010256. doi: 10.3389/fpubh.2022.1010256. eCollection 2022.
3
Phylogenomics and population genomics of SARS-CoV-2 in Mexico during the pre-vaccination stage reveals variants of interest B.1.1.28.4 and B.1.1.222 or B.1.1.519 and the nucleocapsid mutation S194L associated with symptoms.墨西哥在疫苗接种前阶段对 SARS-CoV-2 的系统发生基因组学和群体基因组学研究揭示了与症状相关的感兴趣变体 B.1.1.28.4 和 B.1.1.222 或 B.1.1.519，以及核衣壳突变 S194L。
Microb Genom. 2021 Nov;7(11). doi: 10.1099/mgen.0.000684.
4
Longevity and Neutralizing Capacity of IgG Antibodies against SARS-CoV-2 Generated by the Application of BNT162b2, AZD1222, Convidecia, Sputnik V, and CoronaVac Vaccines: a Cohort Study in the Mexican Population.BNT162b2、AZD1222、Convidecia、Sputnik V 和 CoronaVac 疫苗接种者产生的针对 SARS-CoV-2 的 IgG 抗体的长寿性和中和能力：墨西哥人群的队列研究。
Microbiol Spectr. 2023 Feb 14;11(1):e0237622. doi: 10.1128/spectrum.02376-22. Epub 2023 Jan 5.
5
SARS-CoV-2 Neutralizing Antibodies in Mexican Population: A Five Vaccine Comparison.墨西哥人群中的新型冠状病毒 2 型中和抗体：五种疫苗比较
Diagnostics (Basel). 2023 Mar 22;13(6):1194. doi: 10.3390/diagnostics13061194.
6
Stroke Among SARS-CoV-2 Vaccine Recipients in Mexico: A Nationwide Descriptive Study.墨西哥 SARS-CoV-2 疫苗接种者中的中风：一项全国描述性研究。
Neurology. 2022 May 10;98(19):e1933-e1941. doi: 10.1212/WNL.0000000000200388. Epub 2022 Mar 11.
7
COVID-19 Vaccine Guidance for Patients with Cancer in Mexico: Report From the Working Group of the Mexican Society of Oncology.墨西哥癌症患者的COVID-19疫苗接种指南：墨西哥肿瘤学会工作组报告
Arch Med Res. 2022 Feb;53(2):223-227. doi: 10.1016/j.arcmed.2021.07.005. Epub 2021 Jul 30.
8
Genomic Characterization of SARS-CoV-2 Isolated from Patients with Distinct Disease Outcomes in Mexico.墨西哥不同疾病结局患者分离的 SARS-CoV-2 的基因组特征。
Microbiol Spectr. 2022 Feb 23;10(1):e0124921. doi: 10.1128/spectrum.01249-21. Epub 2022 Jan 12.
9
Bats and humans during the SARS-CoV-2 outbreak: The case of bat-coronaviruses from Mexico.SARS-CoV-2 爆发期间的蝙蝠和人类：来自墨西哥的蝙蝠冠状病毒案例。
Transbound Emerg Dis. 2021 May;68(3):987-992. doi: 10.1111/tbed.13751. Epub 2020 Aug 16.
10
Mortality Due to COVID-19 in Renal Transplant Recipients, Related to Variants of SARS-CoV-2 and Vaccination in Mexico.墨西哥与 SARS-CoV-2 变异株和疫苗接种相关的肾移植受者 COVID-19 死亡率。
Transplant Proc. 2022 Jul-Aug;54(6):1434-1438. doi: 10.1016/j.transproceed.2022.05.010. Epub 2022 Jun 1.
引用本文的文献
1
Impact of COVID-19 Vaccination on Hospitalization and Mortality: A Comparative Analysis of Clinical Outcomes During the Early Phase of the Pandemic.2019冠状病毒病疫苗接种对住院率和死亡率的影响：大流行早期临床结局的比较分析
Infect Dis Rep. 2025 Jun 27;17(4):74. doi: 10.3390/idr17040074.
本文引用的文献
1
Assessing the real-world effectiveness of five SARS-CoV-2 vaccines in a cohort of Mexican pensioners: a nationwide nested test-negative design study.评估5种新冠病毒疫苗在一组墨西哥养老金领取者中的实际效果：一项全国性巢式检测阴性设计研究。
Lancet Reg Health Am. 2023 Oct 19;27:100612. doi: 10.1016/j.lana.2023.100612. eCollection 2023 Nov.
2
The superiority of bivalent over monovalent booster vaccines.二价加强疫苗相对于单价加强疫苗的优越性。
Lancet Infect Dis. 2023 Dec;23(12):1324-1325. doi: 10.1016/S1473-3099(23)00424-3. Epub 2023 Aug 2.
3
COVID-19 vaccination and governance in the case of low, middle and high-income countries.新冠病毒疫苗接种和低、中、高收入国家的治理。
BMC Public Health. 2023 Jun 5;23(1):1073. doi: 10.1186/s12889-023-15975-3.
4
Effectiveness of a nationwide COVID-19 vaccination program in Mexico against symptomatic COVID-19, hospitalizations, and death: a retrospective analysis of national surveillance data.墨西哥全国性 COVID-19 疫苗接种计划对有症状 COVID-19、住院和死亡的有效性：国家监测数据的回顾性分析。
Int J Infect Dis. 2023 Apr;129:188-196. doi: 10.1016/j.ijid.2023.01.040. Epub 2023 Feb 11.
5
Vaccine Effectiveness of CanSino (Adv5-nCoV) Coronavirus Disease 2019 (COVID-19) Vaccine Among Childcare Workers-Mexico, March-December 2021.康希诺（Adv5-nCoV）新冠病毒疫苗对儿童保育工作者的有效性-墨西哥，2021 年 3 月至 12 月。
Clin Infect Dis. 2022 Oct 3;75(Suppl 2):S167-S173. doi: 10.1093/cid/ciac488.
6
[Not Available].[无可用内容]。
Salud Publica Mex. 2022 Apr 8;64(2):131-136. doi: 10.21149/13521.
7
Comprehensive Evaluation of the Impact of Sociodemographic Inequalities on Adverse Outcomes and Excess Mortality During the Coronavirus Disease 2019 (COVID-19) Pandemic in Mexico City.墨西哥城 2019 年冠状病毒病（COVID-19）大流行期间社会人口不平等对不良结局和超额死亡率影响的综合评估。
Clin Infect Dis. 2022 Mar 9;74(5):785-792. doi: 10.1093/cid/ciab577.
8
Five priorities for universal COVID-19 vaccination.全球新冠病毒疫苗接种的五项优先事项。
Lancet. 2021 Jul 24;398(10297):285-286. doi: 10.1016/S0140-6736(21)01371-4. Epub 2021 Jun 18.
Zotero 插件